Menu
Search
|

Menu

Close
X

Zynerba Pharmaceuticals Inc ZYNE.OQ (NASDAQ Stock Exchange Global Market)

10.48 USD
-0.15 (-1.41%)
As of Feb 23
chart
Previous Close 10.63
Open 10.65
Volume 69,876
3m Avg Volume 104,822
Today’s High 10.83
Today’s Low 10.25
52 Week High 25.95
52 Week Low 5.42
Shares Outstanding (mil) 13.55
Market Capitalization (mil) 142.04
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.874
FY16
-2.572
FY15
-1.633
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
--
8.35
Price to Book (MRQ)
vs sector
2.15
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-64.15
13.63
Return on Equity (TTM)
vs sector
-64.47
15.39

EXECUTIVE LEADERSHIP

Armando Anido
Chairman of the Board, Chief Executive Officer, Since 2014
Salary: $535,600.00
Bonus: $337,428.00
Terri Sebree
President, Since 2014
Salary: $412,000.00
Bonus: $256,470.00
James Fickenscher
Chief Financial Officer, Vice President - Corporate Development, Since 2016
Salary: $97,000.00
Bonus: $151,060.00
Suzanne Hanlon
Secretary, General Counsel and Vice President, Human Resources, Since 2014
Salary: $61,538.00
Bonus: --
William Roberts
Vice President - Investor Relations and Corporate Communications, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

80 W. Lancaster Avenue, Suite 30
DEVON   PA   19333

Phone: +1484.5817505
Site: zynerba.com/

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

SPONSORED STORIES